what is glp 1 s The promise and peril of GLP-1 agonists: we do (and don't) know as of August 2024 GLP-1 Medication: Understanding Your Options

While more research is needed, the momentum is undeniable

In individuals with T2DM, chronic hyperglycemia is known to downregulate GIPR expression and impair GIP-stimulated insulinotropic activity, thereby limiting the efficacy of GIP monotherapy [21]

They also trigger the release of insulin from the pancreas and inhibit the secretion of glucagon, a hormone that raises blood sugar levels

It also requires daily injections compared to the weekly dosing schedule of tirzepatide and semaglutide medications

Notably, about one in four of these patients did not carry a type 2 diabetes diagnosis , suggesting that a substantial portion of GLP-1 use is being driven by weight loss and other emerging indications outside of diabetes care (Figure 2)